THE ROLE OF BUSPIRONE FOR THE TREATMENT OF CEREBELLAR ATAXIA IN AN OLDER INDIVIDUAL

Main Article Content

Jayna M Holroyd-Leduc
Barbara A Liu
Brian E Mak I
Aleksandra Zecevic
Nathan Herrmann
Sandra E Black

Keywords

Cerebellar ataxia, buspirone, aged, 80 and over

Abstract

Background


Buspirone, a 5HT-agonist and D2-dopamine antagonist/agonist, has modest beneficial effects in younger individuals with cerebellar ataxia. However, it is unclear whether it is beneficial and tolerable in older ataxic individuals.


 Objective


To determine if an older individual with cerebellar ataxia would benefit from and tolerate buspirone.


 Methods


We performed a single-subject, double-blinded, placebo-controlled randomized-phase study. The 80 year- old subject was to undergo six 4-week testing periods, divided randomly into three treatment and three placebo  arms  with  a  2-week  washout period  between each  arm.  Treatment  consisted of  buspirone hydrochloride. Outcomes were clinical gait and balance testing, posturography testing, and subjective measurement of balance confidence.


 Results


There were no statistically significant objective improvements with buspirone. The subject experienced a subjective improvement in balance confidence and tolerated treatment.


 Conclusions


Single-subject studies can help when it is unclear whether drug trial results with young subjects are generalizable to an older subject. This single-subject study determined that buspirone was tolerable but not clearly beneficial for an ataxic older individual.

Abstract 398 | PDF Downloads 101

References

1. Strahlendorf JC, Lee MH, Strahlendorf HK. Serotonin modulates muscimol- and baclofen- elicited inhibition of cerebellar Purkinje cells. Eur J Pharmacol. 1991;201(2-3):239-242.
2. Strahlendorf JC, Lee M, Strahlendorf HK. Modulatory role of serotonin on GABA-elicited inhibition of cerebellar Purkinje cells. Neuroscience. 1989;30(1):117-125.
3. Trouillas P, Xie J, Adeleine P, et al. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double blind drug placebo study in patients with cerebellar cortical atrophy. Arch Neurol. 1997;54(6):749-752.
4. Lou JS, Goldfarb L, McShane L, Gatev P, Hallett M. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol.
1995;52(10):982-988.
5. Edgington ES. Randomized single-subject experimental designs. Behav Res Ther. 1996;34(7):567-574.
6. Lundin-Olsson L, Nyberg L, Gustafson Y. "Stops walking when talking" as a predictor of falls in elderly people. Lancet. 1997;349(9052):617.
7. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142-148.
8. Maki BE, Holliday PJ, Fernie GR. Aging and postural control. A comparison of spontaneous- and induced-sway balance tests. J Am Geriatr Soc. 1990;38(1):1-9.
9. Powell LE, Myers AM. The Activities-specific Balance Confidence (ABC) Scale. J Gerontol A Biol Sci Med Sci. 1995;50A(1):M28-34.
10. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370.
11. Stata Statistical Software: Release 7.0 program. Stata Corporation; 2001.